Expression of Ganglioside GD2, Reprogram the Lipid Metabolism and EMT Phenotype in Bladder Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 10

PMID 29221154

Citations 34

Authors

Venkatrao Vantaku

Sri Ramya Donepudi

Chandrashekar R Ambati

Feng Jin

Vasanta Putluri

Khoa Nguyen

Kimal Rajapakshe

Cristian Coarfa

Venkata Lokesh Battula

Yair Lotan

Nagireddy Putluri

Affiliations

Soon will be listed here.

Abstract

High-grade Bladder Cancer (BLCA) represents the most aggressive and treatment-resistant cancer that renders the patients with poor survival. However, only a few biomarkers have been identified for the detection and treatment of BLCA. Recent studies show that ganglioside GD2 can be used as cancer biomarker and/or therapeutic target for various cancers. Despite its potential relevance in cancer diagnosis and therapeutics, the role of GD2 is unknown in BLCA. Here, we report for the first time that high-grade BLCA tissues and cell lines have higher expression of GD2 compared to low-grade by high-resolution Mass Spectrometry. The muscle invasive UMUC3 cell line showed high GD2, mesenchymal phenotype, and cell proliferation. Besides, we have shown the cancer stem cells (CSC) property (CD44hiCD24lo) of GD2+ UMUC3 and J82 cells. Also, the evaluation of lipid metabolism in GD2+ BLCA cell lines revealed higher levels of Phosphatidylinositol (PI), Phosphatidic acid (PA), Cardiolipin (CL) and lower levels of Phosphatidylserine (PS), plasmenyl-phosphatidylethanolamines (pPE), plasmenyl-phosphocholines (pPC), sphingomyelins (SM), triglycerides (TGs) and N-Acetylneuraminic acid. These findings are significantly correlated with the tissues of BLCA patients. Based on this evidence, we propose that GD2 may be used as an effective diagnostic and therapeutic target for aggressive BLCA.

Citing Articles

Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.

Visal T, Bayraktar R, den Hollander P, Attathikhun M, Zhou T, Wang J Cancer Res. 2025; 85(5):894-911.

PMID: 39853244 PMC: 11873730. DOI: 10.1158/0008-5472.CAN-24-0400.

Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma.

Mannini A, Pastore M, Giachi A, Correnti M, Spinola Lasso E, Lottini T Liver Int. 2024; 45(1):e16208.

PMID: 39726234 PMC: 11684508. DOI: 10.1111/liv.16208.

Lipid metabolism subtypes reflects the prognosis and immune profiles of bladder cancer patients by NMF clustering and building related signature.

Zhou Z, Chai Y, Li Y, Zhang Y, Wang T Discov Oncol. 2024; 15(1):796.

PMID: 39692922 PMC: 11655945. DOI: 10.1007/s12672-024-01631-8.

Prospects of anti-GD2 immunotherapy for retinoblastoma.

Zhang X, You W, Wang Y, Dejenie R, Wang C, Huang Y Front Immunol. 2024; 15:1499700.

PMID: 39620227 PMC: 11604707. DOI: 10.3389/fimmu.2024.1499700.

Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer.

Kami Reddy K, Piyarathna D, Park J, Putluri V, Amara C, Kamal A JCI Insight. 2024; 9(17).

PMID: 39253977 PMC: 11385078. DOI: 10.1172/jci.insight.172336.

References

Hakomori S . Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol. 2003; 491:369-402. DOI: 10.1007/978-1-4615-1267-7_24. View

Wander S, Zhao D, Besser A, Hong F, Wei J, Ince T . PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2013; 138(2):369-81. PMC: 3608882. DOI: 10.1007/s10549-012-2389-6. View

Miller T, Balko J, Arteaga C . Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011; 29(33):4452-61. PMC: 3221526. DOI: 10.1200/JCO.2010.34.4879. View

Shurin G, Shurin M, Bykovskaia S, Shogan J, Lotze M, Barksdale Jr E . Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 2001; 61(1):363-9. View

Hakomori S . Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996; 56(23):5309-18. View

Clark P, Agarwal N, Biagioli M, Eisenberger M, Greenberg R, Herr H . Bladder cancer. J Natl Compr Canc Netw. 2013; 11(4):446-75. DOI: 10.6004/jnccn.2013.0059. View

Knoepp S, Chahal M, Xie Y, Zhang Z, Brauner D, Hallman M . Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells. Mol Pharmacol. 2008; 74(3):574-84. DOI: 10.1124/mol.107.040105. View

Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

Park M, Ahn B, Hong Y, Min D . Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/NF-kappaB/Sp1-mediated signaling pathways. Carcinogenesis. 2009; 30(2):356-65. DOI: 10.1093/carcin/bgn287. View

10.

Eberlin L, Gabay M, Fan A, Gouw A, Tibshirani R, Felsher D . Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc Natl Acad Sci U S A. 2014; 111(29):10450-5. PMC: 4115527. DOI: 10.1073/pnas.1409778111. View

11.

Groux-Degroote S, Guerardel Y, Julien S, Delannoy P . Gangliosides in breast cancer: new perspectives. Biochemistry (Mosc). 2015; 80(7):808-19. DOI: 10.1134/S0006297915070020. View

12.

Mathe E, Patterson A, Haznadar M, Manna S, Krausz K, Bowman E . Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res. 2014; 74(12):3259-70. PMC: 4100625. DOI: 10.1158/0008-5472.CAN-14-0109. View

13.

Dinney C, McConkey D, Millikan R, Wu X, Bar-Eli M, Adam L . Focus on bladder cancer. Cancer Cell. 2004; 6(2):111-6. DOI: 10.1016/j.ccr.2004.08.002. View

14.

de Chaves E, Sipione S . Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett. 2009; 584(9):1748-59. DOI: 10.1016/j.febslet.2009.12.010. View

15.

Kaufman D, Shipley W, Feldman A . Bladder cancer. Lancet. 2009; 374(9685):239-49. DOI: 10.1016/S0140-6736(09)60491-8. View

16.

Oldenburg D, Ru Y, Weinhaus B, Cash S, Theodorescu D, Guin S . CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL). BMC Cancer. 2016; 16:713. PMC: 5011830. DOI: 10.1186/s12885-016-2756-5. View

17.

Nieman K, Kenny H, Penicka C, Ladanyi A, Buell-Gutbrod R, Zillhardt M . Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011; 17(11):1498-503. PMC: 4157349. DOI: 10.1038/nm.2492. View

18.

Baenke F, Peck B, Miess H, Schulze A . Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013; 6(6):1353-63. PMC: 3820259. DOI: 10.1242/dmm.011338. View

19.

Resnick M, Bassett J, Clark P . Management of superficial and muscle-invasive urothelial cancers of the bladder. Curr Opin Oncol. 2013; 25(3):281-8. DOI: 10.1097/CCO.0b013e32835eb583. View

20.

Dong C, Yuan T, Wu Y, Wang Y, Fan T, Miriyala S . Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013; 23(3):316-31. PMC: 3703516. DOI: 10.1016/j.ccr.2013.01.022. View